UY38243A - Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos - Google Patents
Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usosInfo
- Publication number
- UY38243A UY38243A UY0001038243A UY38243A UY38243A UY 38243 A UY38243 A UY 38243A UY 0001038243 A UY0001038243 A UY 0001038243A UY 38243 A UY38243 A UY 38243A UY 38243 A UY38243 A UY 38243A
- Authority
- UY
- Uruguay
- Prior art keywords
- monospecific
- specific anti
- tmeff2 antibodies
- antibodies
- tmeff2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
La descripción proporcionada en la presente descripción se refiere a anticuerpos anti-TMEFF2 monoespecíficos y multiespecíficos, y a métodos para producir y usar los anticuerpos descritos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862675957P | 2018-05-24 | 2018-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38243A true UY38243A (es) | 2019-11-29 |
Family
ID=67211771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038243A UY38243A (es) | 2018-05-24 | 2019-05-24 | Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos |
Country Status (25)
Country | Link |
---|---|
US (1) | US11866499B2 (es) |
EP (1) | EP3802607A2 (es) |
JP (1) | JP2021524255A (es) |
KR (1) | KR20210011999A (es) |
CN (1) | CN112703203A (es) |
AR (1) | AR115419A1 (es) |
AU (1) | AU2019274652A1 (es) |
BR (1) | BR112020023416A2 (es) |
CA (1) | CA3101304A1 (es) |
CL (1) | CL2020003032A1 (es) |
CO (1) | CO2020014515A2 (es) |
CR (1) | CR20200564A (es) |
EA (1) | EA202092849A1 (es) |
EC (1) | ECSP20075234A (es) |
IL (1) | IL278862A (es) |
JO (1) | JOP20200295A1 (es) |
MA (1) | MA52772A (es) |
MX (1) | MX2020012589A (es) |
NI (1) | NI202000087A (es) |
PE (1) | PE20210634A1 (es) |
PH (1) | PH12020551948A1 (es) |
SG (1) | SG11202011268VA (es) |
TW (1) | TW202003584A (es) |
UY (1) | UY38243A (es) |
WO (1) | WO2019224713A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200302A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | الأجسام المضادة لـ cd3 واستخداماتها |
CN115175702A (zh) * | 2019-12-18 | 2022-10-11 | 詹森生物科技公司 | 用于体内生物靶向的材料和方法 |
US20230374140A1 (en) * | 2020-10-09 | 2023-11-23 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
EP4228693A1 (en) | 2020-10-13 | 2023-08-23 | Janssen Biotech, Inc. | Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii |
WO2023164510A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
WO2024052831A1 (en) * | 2022-09-09 | 2024-03-14 | Janssen Biotech, Inc. | Method of treating cancer with an anti tmeff2xcd3 bispecific antibody |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US226A (en) | 1837-06-03 | Samuel goss | ||
US7709A (en) | 1850-10-08 | Chas S Gaylord | Improved spring-grapple | |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
CA2150262C (en) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Multivalent and multispecific binding proteins, their manufacture and use |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
CA2478683C (en) | 2002-03-08 | 2016-01-26 | Protein Design Labs, Inc. | Antibodies against cancer antigen tmeff2 and uses thereof |
CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
CA2646965C (en) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Engineered heterodimeric protein domains |
EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US20100261620A1 (en) | 2008-10-14 | 2010-10-14 | Juan Carlos Almagro | Methods of Humanizing and Affinity-Maturing Antibodies |
WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CN103097417B (zh) | 2010-04-20 | 2019-04-09 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
WO2013063702A1 (en) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
WO2013093122A2 (en) * | 2011-12-23 | 2013-06-27 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
PT3653049T (pt) | 2012-12-14 | 2023-11-14 | Omniab Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
BR112015022971B1 (pt) | 2013-03-15 | 2022-05-17 | Janssen Biologics B.V. | Métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes |
TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
LT3189081T (lt) | 2014-09-05 | 2020-05-11 | Janssen Pharmaceutica Nv | Cd123 surišantys agentai ir jų naudojimas |
WO2016179003A1 (en) | 2015-05-01 | 2016-11-10 | Genentech, Inc. | Masked anti-cd3 antibodies and methods of use |
WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
BR112018008904A2 (pt) * | 2015-11-03 | 2018-11-27 | Janssen Biotech Inc | anticorpos que se ligam especificamente a tim-3 e seus usos |
CA3100157A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics |
JOP20200302A1 (ar) | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | الأجسام المضادة لـ cd3 واستخداماتها |
-
2019
- 2019-05-21 WO PCT/IB2019/054184 patent/WO2019224713A2/en unknown
- 2019-05-21 SG SG11202011268VA patent/SG11202011268VA/en unknown
- 2019-05-21 JP JP2020565399A patent/JP2021524255A/ja active Pending
- 2019-05-21 MX MX2020012589A patent/MX2020012589A/es unknown
- 2019-05-21 CA CA3101304A patent/CA3101304A1/en active Pending
- 2019-05-21 EP EP19737217.0A patent/EP3802607A2/en active Pending
- 2019-05-21 EA EA202092849A patent/EA202092849A1/ru unknown
- 2019-05-21 PE PE2020001881A patent/PE20210634A1/es unknown
- 2019-05-21 CN CN201980034951.1A patent/CN112703203A/zh active Pending
- 2019-05-21 JO JOP/2020/0295A patent/JOP20200295A1/ar unknown
- 2019-05-21 KR KR1020207036922A patent/KR20210011999A/ko active Search and Examination
- 2019-05-21 US US16/417,889 patent/US11866499B2/en active Active
- 2019-05-21 AU AU2019274652A patent/AU2019274652A1/en active Pending
- 2019-05-21 BR BR112020023416-8A patent/BR112020023416A2/pt unknown
- 2019-05-21 MA MA052772A patent/MA52772A/fr unknown
- 2019-05-21 CR CR20200564A patent/CR20200564A/es unknown
- 2019-05-22 TW TW108117613A patent/TW202003584A/zh unknown
- 2019-05-24 AR ARP190101399A patent/AR115419A1/es unknown
- 2019-05-24 UY UY0001038243A patent/UY38243A/es unknown
-
2020
- 2020-11-13 PH PH12020551948A patent/PH12020551948A1/en unknown
- 2020-11-19 IL IL278862A patent/IL278862A/en unknown
- 2020-11-23 NI NI202000087A patent/NI202000087A/es unknown
- 2020-11-23 CO CONC2020/0014515A patent/CO2020014515A2/es unknown
- 2020-11-23 CL CL2020003032A patent/CL2020003032A1/es unknown
- 2020-11-23 EC ECSENADI202075234A patent/ECSP20075234A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3101304A1 (en) | 2019-11-28 |
SG11202011268VA (en) | 2020-12-30 |
AU2019274652A1 (en) | 2020-11-26 |
MA52772A (fr) | 2021-04-14 |
US11866499B2 (en) | 2024-01-09 |
AR115419A1 (es) | 2021-01-13 |
CN112703203A (zh) | 2021-04-23 |
WO2019224713A2 (en) | 2019-11-28 |
EP3802607A2 (en) | 2021-04-14 |
EA202092849A1 (ru) | 2021-03-16 |
MX2020012589A (es) | 2021-01-29 |
ECSP20075234A (es) | 2020-12-31 |
PH12020551948A1 (en) | 2021-08-16 |
KR20210011999A (ko) | 2021-02-02 |
JOP20200295A1 (ar) | 2020-11-22 |
TW202003584A (zh) | 2020-01-16 |
PE20210634A1 (es) | 2021-03-23 |
CR20200564A (es) | 2021-06-21 |
JP2021524255A (ja) | 2021-09-13 |
NI202000087A (es) | 2021-03-23 |
IL278862A (en) | 2021-01-31 |
BR112020023416A2 (pt) | 2021-02-17 |
US20190359711A1 (en) | 2019-11-28 |
CL2020003032A1 (es) | 2021-04-16 |
WO2019224713A3 (en) | 2020-01-02 |
CO2020014515A2 (es) | 2020-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38243A (es) | Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos | |
CL2019002824A1 (es) | Anticuerpos anti-lag3. | |
PE20211603A1 (es) | Anticuerpos que se unen a cd3 | |
CL2019002793A1 (es) | Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma. | |
ECSP19026178A (es) | Anticuerpos anti-pd-1 y sus usos | |
CL2017003356A1 (es) | Moduladores cot y métodos de uso de los mismos | |
CR20180151A (es) | Antcuierpos anti-pd1 y métodos de uso | |
ECSP19050049A (es) | Anticuerpos anti-ox40 y sus usos | |
ECSP18094829A (es) | Anticuerpos anti-cd40 y sus usos | |
ECSP14005975A (es) | Anticuerpos anti-PHF-tau y sus usos | |
CO2020015172A2 (es) | Anticuerpos biespecíficos contra dll3-cd3 | |
CO2020012347A2 (es) | Anticuerpos anti-hla-g y usos de los mismos. | |
CL2017001632A1 (es) | Manufactura de proteína. | |
CO2018001420A2 (es) | Biomasa rica en proteína de traustoquitridios, método de cultivo y utilización | |
AR115052A1 (es) | Anticuerpos multiespecíficos y utilización de los mismos | |
AR112587A1 (es) | Psicosa-6-fosfato fosfatasa, composición para producir d-psicosa que comprende la enzima y métodos para producir d-psicosa utilizando la enzima | |
AR113695A1 (es) | Una d-psicosa 3-epimerasa y el uso de un método para producir d-psicosa | |
AR117642A1 (es) | Fructosa-c4-epimerasa y método de producción de tagatosa usando la misma | |
DOP2017000264A (es) | Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio | |
UY37467A (es) | Método para crear un compuesto a base de mercurio, compuesto a base de mercurio, métodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio | |
CL2016001884A1 (es) | Método para sintetizar florfenicol. | |
UA101710U (xx) | Знімне туалетне сидіння | |
UA104842U (uk) | Застосування біс(2,2,2-трифлуоретил)карбонату як конденсуючого реагента в однореакторному паралельному синтезі несиметричних аліфатичних сечовин |